Management of early rheumatoid arthritis

Journal of Association of Physicians of India

Volumn 55, Issue MAY, 2007, Pages 355-362

  Suresh, E ^a  

^a KETTERING GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ALTERNATIVE MEDICINE; CHRONIC DISEASE; HUMAN; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW; RHEUMATOID ARTHRITIS; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COMPLEMENTARY THERAPIES; HUMANS; PATIENT CARE TEAM; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247895554     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Malaviya AN, Kapoor SK, Singh RR, et al. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 1993;13:131-4.
2. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
3. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475-9.
4. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis 2002;61:335-40.
5. Aggarwal A, Chandran S, Misra R. Physical, psychosocial and economic impact of rheumatoid arthritis: a pilot study of patients seen at a tertiary care referral centre. Natl Med J India 2006;19:187-91.
6. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
7. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57:350-6.
8. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
9. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
10. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43: 22-9.
11. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
12. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.
13. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3-year follow-up on the hydroxyxhloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27:623-9.
14. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:S154-7.
15. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996;124:773-4.
16. Emery P. Prognosis in inflammatory arthritis: the value of HLA genotyping and oncological analogy. The Dunlop Dotteridge Lecture. Journal of Rheumatology 1997;37:1166-70.
17. Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know. J R Soc Med 2004;97:421-4.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Dugowson CE, Nelson JL, Koepsell TD. Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patients. Arthritis Rheum 1990;33:1042-6.
20. Quinn MA, Green MJ, Marzo-Ortega H, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003;48:3039-45.
21. Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999;42:2184-8.
22. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
23. Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.
24. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
25. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006;45:478-80.
26. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32:231-8.
27. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
28. Hitchon CA, Peschken CA, Shaik S, El-Gabalawy HS. Early undifferentiated arthritis. Rheum Dis Clin North Am 2005;31:605-26.
29. Smolen JS, Aletaha D, Steiner CW, et al. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77.
30. Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care 1998;36:513-22.
31. Luqmani RA, Hennell S, Estrach C, et al. British Society for Rheumatology and British health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006;45:1167-9.
32. Weinblatt ME. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995;34:43-8.
33. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
34. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
35. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
36. Chakravarty K, McDonald H, Pullar T, et al. BSR and BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2006 Sep 27; [Epub ahead of print].
37. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
38. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
39. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
40. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
41. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
42. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
43. Goekoop-Ruiterman YP, de Vries Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
44. Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62.
45. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
46. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
47. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
48. Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis. Ann Rheum Dis 2005;64:1252-6.
49. Van der Bijl AE, Goekoop-Ruiterman YP, Breedveld FC, et al. Initial combination therapy with infliximab and methotrexate can suppress rheumatoid arthritis activity after infliximab discontinuation. Arthritis Rheum 2005;52:S346.
50. Emery P. Treatment of rheumatoid arthritis. BMJ 2006;332:152-5.
51. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
52. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
53. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population bases nested case-control analysis. BMJ 2005;330:1366.
54. Conaghan P, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage. Arthritis Rheum 2003;48:64-71.
55. Corkill MM, Kirkham BW, Chikanza IC, et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol 1990;29:274-9.
56. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
57. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-8.
58. Hammond A. What is the role of the occupational therapist? Best Pract Res Clin Rheumatol 2004;18:491-505.
59. Fransen M. When is physiotherapy appropriate? Best Pract Res Clin Rheumatol 2004;18:477-89.
60. Chandrashekara S, Anilkumar T, Jamuna S. Complementary and alternative drug therapy in arthritis. J Assoc Physicians India 2002;50:225-7.
61. Taibi DM, Bourguignon C. The role of complementary and alternative therapies in managing rheumatoid arthritis. Fam Community Health 2003;26:41-52.
62. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med 1993;119:867-73.
63. Skoldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:208-14.
64. Kjeldsen-Kragh J, Haughen M, Borchgrevink CF, et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet 1991;338:899-902.
65. Beri D, Malaviya AN, Shandilya R, Singh RR. Effect of dietary restrictions on disease activity in rheumatoid arthritis. Ann Rheum Dis 1988;47:69-72.
66. Cleland LG, Caughey GE, James MJ, Proudman SM. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol 2006;33:1973-9.
67. Grover S. Sinha RP, Singh U, et al. Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol 2006;33:244-7.
68. Chogle AR, Chakravarty A. Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis: emerging concepts, early diagnosis and management. J Assoc Physicians India 2007;55:32-40.
69. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003;42:607-13.
70. Van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
71. Costenbader KH, Coblyn JS. Statin therapy in rheumatoid arthritis. South Med J 2005;98:534-40.
72. Maradit-Kremers H, Crowson CS, Nicola OJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11.
73. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
74. Malaviya AN. Cytokine network and its manipulation in rheumatoid arthritis. J Assoc Physicians India 2006;54:15-8.
75. Chopra A. The WHO-ILAR COPCORD Bhigwan (India) model: foundation for a future COPCORD design and data repository. Clin Rheumatol 2006;25:443-7